

References

1. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Washington (DC): National Academies Press (US); 2011.
2. Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development in precision oncology. *Nature*. 2015;526(7573):361-70.
3. Fine LG. A 2000-year history of nephrology: 10 enduring scientific landmarks. *J Nephrol*. 2013;26(Suppl. 22):6-17.
4. Cameron JS, Hicks J. The introduction of renal biopsy into nephrology from 1901 to 1961: a paradigm of the forming of nephrology by technology. *Am J Nephrol*. 1997;17(3-4):347-58.
5. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Annals of the rheumatic diseases*. 2016.
6. Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis*. 2016;67(3 Suppl 1):Svii, S1-305.
7. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010;375(9731):2073-81.
8. Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. *Nature reviews Nephrology*. 2016;12(3):133-46.
9. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. *European journal of human genetics : EJHG*. 2011;19(6):617-23.
10. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nature genetics*. 1994;7:85-90.
11. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature*. 1999;399:271-5.
12. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. *The Journal of biological chemistry*. 2000;275(33):25733-41.
13. Singer EA, Gupta GN, Srinivasan R. Update on targeted therapies for clear cell renal cell carcinoma. *Curr Opin Oncol*. 2011;23(3):283-9.
14. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologues define a family of dioxygenases that regulate HIF by prolyl hydroxylation. *Cell*. 2001;107:43-54.
15. Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. *Nature reviews Nephrology*. 2016;12(3):157-68.
16. Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. *Lancet*. 2010;376(9743):794-801.
17. Athanasiou Y, Voskarides K, Gale DP, Damianou L, Patsias C, Zavros M, et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. *Clinical journal of the American Society of Nephrology : CJASN*. 2011;6(6):1436-46.

18. Vernon KA, Gale DP, de Jorge EG, McLean AG, Galliford J, Pierides A, et al. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2011;11(1):152-5.
19. Vernon KA, Goicoechea de Jorge E, Hall AE, Fremeaux-Bacchi V, Aitman TJ, Cook HT, et al. Acute Presentation and Persistent Glomerulonephritis Following Streptococcal Infection in a Patient With Heterozygous Complement Factor H-Related Protein 5 Deficiency. *Am J Kidney Dis*. 2012.
20. Chen Q, Manzke M, Hartmann A, Buttner M, Amann K, Pauly D, et al. Complement Factor H-Related 5-Hybrid Proteins Anchor Properdin and Activate Complement at Self-Surfaces. *Journal of the American Society of Nephrology : JASN*. 2016;27(5):1413-25.
21. Chen Q, Wiesener M, Eberhardt HU, Hartmann A, Uzonyi B, Kirschfink M, et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. *The Journal of clinical investigation*. 2014;124(1):145-55.
22. Reeders ST, Breuning MH, Davies KE, Nicholls RD, Jarman AP, Higgs DR, et al. A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16. *Nature*. 1985;317(6037):542-4.
23. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. *Cell*. 1994;78(4):725.
24. Ong AC, Harris PC. A polycystin-centric view of cyst formation and disease: the polycystins revisited. *Kidney Int*. 2015;88(4):699-710.
25. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med*. 2012;367(25):2407-18.
26. NICE. Tolvaptan for treating autosomal dominant polycystic kidney disease [TA358]. 2015.
27. Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2016;31(3):337-48.